KYG2545C1042
KYG2545C1042
Crescent Biopharma, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 |
|---|---|---|---|
Market & Enterprise Value | |||
Market Cap | 553.86M EUR | 499.66M EUR | 506.55M EUR |
Enterprise Value | 438.19M EUR | 329.5M EUR | 318.93M EUR |
Valuation Multiples | |||
Trailing P/E | -- | -- | -- |
Forward P/E | -5.67x | -- | -- |
Price to Sales | 46.61x | 42.05x | 42.63x |
Price to Book | 3.13x | 3.06x | 2.76x |
EV/Revenue | 36.88x | 27.73x | 26.84x |
EV/EBITDA | -2.58x | -- | -- |
Price to FCF (P/FCF) | -- | -- | -- |
EV/FCF | -- | -- | -- |
FCF Yield | -- | -30.74% | -29.75% |